1995: RCTs of dose and durationPoynard, et al., N Engl J Med; 332: 1457-62

Study validity:

• Strengths

- Large, multicenter study; good randomization.

- Reasons for drop-outs clearly stated and ITT analysis used.

• Weaknesses

- > 10 % HCV Ab negative.

- Difficult to discern what happened to untreated group, but ITT analysis should keep these variables from affecting outcomes measured.

- Again, ? clinical significance of outcomes.

- Supported by Schering-Plough.

Previous slide

Next slide

Back to first slide

View graphic version